Literature DB >> 9888443

Ethambutol is toxic to retinal ganglion cells via an excitotoxic pathway.

J E Heng1, C K Vorwerk, E Lessell, D Zurakowski, L A Levin, E B Dreyer.   

Abstract

PURPOSE: Ethambutol is an essential medication in the management of tuberculosis. However, it can cause an optic neuropathy of uncertain etiology. Ethambutol toxicity was therefore studied in rodent retinal cells, and agents that might block its toxicity were considered.
METHODS: The toxicity of ethambutol and related agents was evaluated in rodent retinal dissociated cell preparations and whole eyes. Calcium fluxes and mitochondrial function were evaluated by fluorescent and staining techniques. For in vivo assays, adult rats were administered oral ethambutol over a 3-month period. Cell survival was assessed by stereology.
RESULTS: Ethambutol is specifically toxic to retinal ganglion cells in vitro and in vivo. Endogenous glutamate is necessary for the full expression of ethambutol toxicity, and glutamate antagonists prevent ethambutol-mediated cell loss. Ethambutol causes a decrease in cytosolic calcium, an increase in mitochondrial calcium, and an increase in the mitochondrial membrane potential.
CONCLUSIONS: The visual loss associated with ethambutol may be mediated through an excitotoxic pathway, inasmuch as ganglion cells are rendered sensitive to normally tolerated levels of extracellular glutamate. Ethambutol perturbs mitochondrial function. Its toxicity may depend on decreased ATPase activity and mitochondrial energy homeostasis. Glutamate antagonists may be useful in limiting the side effects seen with ethambutol.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9888443

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  21 in total

1.  Multifocal electroretinogram demonstrated macular toxicity associated with ethambutol related optic neuropathy.

Authors:  T Y Y Lai; W-M Chan; D S C Lam; E Lim
Journal:  Br J Ophthalmol       Date:  2005-06       Impact factor: 4.638

2.  Effects of intraocular rifampicin on retinal ganglion cell structure: a stereological and histopathological study.

Authors:  Ozgür Cakici; Selina Aksak; Deniz Unal; Sare Sipal; Sadullah Keles; Talha Dumlu; Murat Karamese
Journal:  Int J Ophthalmol       Date:  2013-10-18       Impact factor: 1.779

3.  Drug-induced myopathy in a patient with pulmonary tuberculosis.

Authors:  Rajiv Shah; Pradhib Venkatesan
Journal:  BMJ Case Rep       Date:  2015-07-15

4.  Spectrum and Clinical Course of Visual Field Abnormalities in Ethambutol Toxicity.

Authors:  Thomas Mendel; David Fleischman; R Rand Allingham; Henry Tseng; David A Chesnutt
Journal:  Neuroophthalmology       Date:  2016-04-29

5.  The efficacy of latent tuberculosis treatment for immunocompetent uveitis patients with a positive T-SPOT.TB test: 6-year experience in a tuberculosis endemic region.

Authors:  Chung Yee Chung; Kenneth K W Li
Journal:  Int Ophthalmol       Date:  2017-09-25       Impact factor: 2.031

Review 6.  Mitochondrial fusion, fission, and mitochondrial toxicity.

Authors:  Joel N Meyer; Tess C Leuthner; Anthony L Luz
Journal:  Toxicology       Date:  2017-08-05       Impact factor: 4.221

Review 7.  Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies.

Authors:  Patrick Yu-Wai-Man; Philip G Griffiths; Patrick F Chinnery
Journal:  Prog Retin Eye Res       Date:  2010-11-26       Impact factor: 21.198

Review 8.  Toxic optic neuropathy.

Authors:  Anat Kesler; Pazit Pianka
Journal:  Curr Neurol Neurosci Rep       Date:  2003-09       Impact factor: 5.081

9.  SIRT1 activating compounds reduce oxidative stress and prevent cell death in neuronal cells.

Authors:  Reas S Khan; Zoe Fonseca-Kelly; Catherine Callinan; Ling Zuo; Mira M Sachdeva; Kenneth S Shindler
Journal:  Front Cell Neurosci       Date:  2012-12-31       Impact factor: 5.505

10.  Toxic optic neuropathy.

Authors:  Pradeep Sharma; Reena Sharma
Journal:  Indian J Ophthalmol       Date:  2011 Mar-Apr       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.